About XP Diagnostics
Effective, affordable solutions for early detection
XP Diagnostics focuses on the development and commercialization of rapid, point-of-care, low-cost, and easy-to-use infectious disease screening tests and oral dissolvable biosensors. Our purpose is to detect infections as early as possible with a vision to enable better treatment or containment measures.
Working Together
3a Diagnostics and XP Diagnostics
Diagnostics for Anyone, Anywhere, Anytime
3a Diagnostics is a German-based biotechnology research company specializing in the development, production, and marketing of point-of-care test systems. Their name refers to a belief that solutions should be developed for “anyone” (no specialized training required), “anywhere” (no power or additional equipment required) and “anytime” (decentralized and rapidly deployable).
XP Diagnostics brings together the expertise of 3a with the innovative drug delivery methods from Vektor Pharma with a goal of revolutionizing diagnostics and creating low-cost options with high impact.
Exclusive Global Commercialization Agreement
This exclusive agreement announced in April 2020 paved the way for the development and commercialization of rapid, point-of-care, low-cost, and easy-to-use infectious disease screening tests which include a COVID-19 (saliva-based) lateral flow assay and oral dissolvable biosensors for pandemic threats and dental health applications. This agreement was amended in July 2020 to include 3a’s proprietary enhanced RNA system, related IP and exclusive commercialization rights for the rapid test and RT-PCR test.
“The role of diagnostics in our lives today feels so relevant given the global pandemic. The impact innovation can have in this space at the moment is an exciting opportunity for XPhyto to explore.”
– Hugh Rogers, CEO
Our Products
Peri-implantitis Oral Biosensor
This biosensor allows for early detection of infection associated with dental implants. Planning to launch in late 2021, our affordable solution will be able to help stop the progression of infections and catch the issues as early as possible.
Swine & Avian Flu (H1N1 & H5N1) Oral Biosensors
Aiming for launch in late 2021, this biosensor will help with early detection of highly pathogenic influenza A strains.
COVID-19 LFA Screening Test
This affordable, self-administered test is expected to launch in 2021 with the potential to enable individuals to get tested anytime and anywhere they need – with results in under 15 minutes.
Be in the know. Get our press releases and latest news first.
Hear about our latest research, products, exclusive partnerships & more.